Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

Randomized Study of the Immunogenicity and Duration of Antibody Response Against Circulating SARS-CoV-2 Variant and Influenza Viruses Following Concomitant Versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Cell Culture-based Influenza Vaccine Among Children and Adults

This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.

Study Overview

• Status: Completed
• Conditions: COVID-19; Influenza
• Intervention / Treatment: Biological: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster); Biological: Sequential Vaccination (Influenza vaccine then mRNA COVID booster); Biological: Sequential Vaccination (mRNA COVID booster then Influenza vaccine)

Detailed Description

This study is a prospective, randomized comparative immunogenicity study in an enrolled cohort. During this study, eligible participants will be randomly assigned to receive an approved quadrivalent cell culture-based influenza vaccine (ccIIV4, Seqirus) and an approved mRNA COVID-19 vaccine (Moderna) either concomitantly or sequentially, 28 days apart. Participants (aged 6-11 years and 18-64 years) will be enrolled in the 2023-2024 influenza season.

Demographic and health data (including influenza and COVID-19 vaccination and infection history) will be collected upon enrollment. Enrolled participants will be randomized to one of the following interventions (2:1:1) (i) concomitant administration of the mRNA COVID-19 vaccine (Moderna) and quadrivalent influenza vaccine (ccIIV4, Seqirus); (ii)sequential administration of the quadrivalent influenza vaccine (ccIIV4, Seqirus) at Visit 1 (day 0) and the mRNA COVID-19 vaccine(Moderna) at Visit 2 (day 28); (iii) sequential administration of the mRNA COVID-19 vaccine (Moderna) at Visit 1 (day 0) followed by the quadrivalent influenza vaccine (ccIIV4, Seqirus) at Visit 2 (day 28). Participants will not be blinded to vaccine group.

Whole blood samples to isolate sera for immune assays will be collected prior to vaccination administration at Visit 1 (day 0), Visit 2 (day 28) Visit 3 (day 56; post-vaccination 2) and Visit 4 (day180; end of local flu circulation). Blood samples to isolate PBMC and plasma will be collected from a subset of 250 participants (200 adults and 50 children). If participants exhibit ARI during the study period, the participants may be asked to present for collection of a nasal swab for viral testing for acute influenza or SARS-CoV-2 infection (within 10 days after symptom onset), and blood specimen to isolate sera for immune assays. For participants with confirmed acute infection, the participants may be asked to present for collection of a convalescent-phase blood specimen approximately 28 days after acute visit for isolation of sera, PBMC and plasma.

• Study Type: Interventional
• Enrollment (Actual): 455
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85008
      • Valleywise Health Comprehensive Health Center
    • Tempe, Arizona, United States, 85281
      • ASU Biodesign Institute
  • Georgia
    • Atlanta, Georgia, United States, 30333
      • Centers for Disease Control and Prevention
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University IDCRU
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • University Hospitals Cleveland Medical Center
    • Cleveland, Ohio, United States, 44106
      • VA Northeast Ohio Healthcare System (VANEOHS)
    • South Euclid, Ohio, United States, 44121
      • Senders Pediatrics
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15260
      • Department of Family Medicine, University of Pittsburgh School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy children aged 6-11 years and healthy adults aged 18-64 years that have not received the current season's influenza vaccination or a mRNA COVID-19 vaccination in the past 6 months and have already completed at least a two-dose primary series of an mRNA COVID-19 vaccination
• English or Spanish literate
• Email or text message capability for weekly follow-up
• Intention of receiving influenza vaccine and mRNA COVID-19 vaccine based on ACIP-CDC guidelines
• Willing to provide written/electronic informed consent
• Intention of being available for entire study period and able to complete all relevant study procedures, including follow-up phone calls and clinic visits

Exclusion Criteria:

• Self-reported COVID-19 infection within 3 months prior to enrollment
• Received COVID-19 vaccine within 6 months prior to enrollment
• Received influenza vaccine during the respective influenza season in which the participants are being enrolled
• < 9 years of age and recommended to receive two doses of IIV4 during the respective influenza season in which they are being enrolled
• History of severe allergic reaction after a previous dose of any influenza or COVID-19 mRNA vaccine; or to an influenza or COVID-19 mRNA vaccine component
• Receipt of any licensed vaccine within 6 weeks prior to enrollment in this study or planning receipt of any vaccines within 4 weeks after the receipt of the second vaccine dose administered during study procedures

• Has an immunocompromising condition or taking immunosuppressive medication*

  * Received oral, intramuscular or intravenous systemic immunosuppressants, or immune modifying drugs for >14 days in total within 6 months prior to any study vaccine dose (for corticosteroids ≥ 20 mg/day of prednisone equivalent).

  ** Note: Topical medications are allowed

• Received immunoglobulin, SARS-CoV-2 immunoglobulin, SARS-CoV-2 monoclonal antibody, or blood-derived products, within 3 months prior any study vaccine dose.
• History of Guillain-Barré syndrome
• History of myocarditis or pericarditis
• History of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A)
• Currently pregnant, planning to become pregnant within the first three months of the study per participant self-report or likely to be pregnant per screening criteria
• Bleeding disorder diagnosed by a healthcare provider or bleeding difficulties with intramuscular injections or blood draws.
• Has injury or other reason why deltoid site on both arms cannot be used for vaccinations
• Any condition which, in the opinion of the investigators, may pose a health risk to the participant or interfere with the evaluation of the study objectives
• Temporary Delay Criteria: History of febrile illness (> 100.0°F or 37.8°C) within the past 72 hours prior to vaccine administration

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group i: Concomitant Vaccination; Concomitant Vaccination (Influenza vaccine and mRNA COVID booster) at Visit 1	Biological: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster); Influenza vaccination and mRNA COVID-19 booster will be given at Visit 1.
Experimental: Group ii: Influenza Vaccination at Visit 1; Sequential vaccination with Influenza vaccination at Visit 1 and mRNA COVID booster at Visit 2	Biological: Sequential Vaccination (Influenza vaccine then mRNA COVID booster); Influenza vaccine will be given at Visit 1 and mRNA COVID booster will be given at Visit 2.
Experimental: Group iii: mRNA COVID-19 Vaccination at Visit 1; Sequential vaccination with mRNA COVID booster at Visit 1 and Influenza vaccination at Visit 2	Biological: Sequential Vaccination (mRNA COVID booster then Influenza vaccine); mRNA COVID booster will be given at Visit 1 and Influenza vaccine will be given at Visit 2.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With HAI Seroconversion	Number of participants with a seroconversion HAI Titer ≥1:40 at Day 29 if Day 1 titer is <1:10 or a four-fold rise at Day 29 if Day 1 titer is ≥1:10 for each ccIIV4 antigen in the 2023-2024 influenza season.	Visit 1 (day 1; baseline) to Visit 2 (days 28-42; post-vaccination) for all arms/groups
Percentage of Participants With HAI Seroprotection	Number of participants with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each ccIIV4 antigen in the 2023-2024 influenza season.	Visit 1 (day 1; baseline; pre-immunization) and Visit 2 (days 28-42; post-immunization) for all arms/groups
HAI Geometric Mean Titer	The geometric mean HAI titer (GMT) for each ccIIV4 antigen in the 2023-2024 influenza season. GMTs were derived by using the anti-log of the mean of the log transformed titers.	Visit 1 (day 1; baseline; pre-immunization) and Visit 2 (days 28-42; post-immunization) for all arms/groups
HAI Geometric Mean Fold Rise (GMFR)	GMFRs and 95% confidence intervals were calculated using a t-distribution on log 2-transformed titers.	Visit 1 (day 1; baseline) to Visit 2 (days 28-42; post-vaccination) for all arms/groups

Collaborators and Investigators

• Sponsor: Duke University
• Collaborators: Washington University School of Medicine; University of Pittsburgh; Centers for Disease Control and Prevention; University Hospitals Cleveland Medical Center; Arizona State University; Valleywise Health; Senders Pediatrics; Cleveland VA Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): September 25, 2023
• Primary Completion (Actual): March 7, 2024
• Study Completion (Actual): May 17, 2024

Study Registration Dates

• First Submitted: August 30, 2023
• First Submitted That Met QC Criteria: August 30, 2023
• First Posted (Actual): August 31, 2023

Study Record Updates

• Last Update Posted (Actual): June 13, 2025
• Last Update Submitted That Met QC Criteria: June 11, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Keywords: Influenza; COVID-19; Reactogenicity; Health; Immunogencity
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; COVID-19; Influenza, Human; Immunologic Factors; Physiological Effects of Drugs; Vaccines
• Other Study ID Numbers: Pro00113674

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes